An interventional study of Nintendo Switch-Based Exergame Physical Activity Promotion Intervention in Congenital Heart Disease and Physical Inactivity, sponsored by The Children's Hospital of Zhejiang University School of Medicine. Not yet recruiting at 1 site in China. Open to participants aged 8 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-05-18.
Sponsored by The Children's Hospital of Zhejiang University School of Medicine · Not applicable, Interventional, and Supportive care
The goal of this clinical trial is to learn whether a Nintendo Switch-based exergame physical activity program can help children and adolescents with congenital heart disease increase their physical activity. It will also learn about the safety, acceptability, and feasibility of this program. The study will include children and adolescents aged 8 to 18 years who have congenital heart disease, have received surgical or interventional treatment, and are clinically stable.
The main questions it aims to answer are:
Does the exergame-based program increase the amount of time participants spend in moderate-to-vigorous physical activity each day? Is the exergame-based program safe, acceptable, and feasible for children and adolescents with congenital heart disease?
All participants will receive the same exergame-based physical activity program. Researchers will use different baseline observation periods to help understand whether changes in physical activity happen after the program starts.
Participants will:
Wear an activity monitor to measure daily physical activity. Complete a baseline observation period lasting 7, 14, or 21 days. Take part in a 12-week Nintendo Switch-based exergame physical activity program with guidance, goal setting, self-monitoring, feedback, and caregiver support.
Complete a 2-week observation period after the program to see whether physical activity changes are maintained.
Complete study assessments at screening, the end of baseline, week 4, week 8, week 12, and the end of the observation period.
Researchers will also collect information on step counts, energy expenditure, self-reported physical activity, exercise capacity, quality of life, adherence, acceptability, and adverse events.
Regular physical activity is important for physical function, exercise capacity, psychosocial development, quality of life, and long-term cardiovascular health in children and adolescents with congenital heart disease. However, this population may experience insufficient physical activity and increased sedentary behavior because of disease-related factors, parental concerns about exercise risk, long-term perceptions of exercise restriction, reduced physical fitness, and psychosocial barriers.
Exergames combine physical movement with interactive game-based tasks and may be suitable for children and adolescents because they are engaging, easy to access, and provide immediate feedback. Nintendo Switch motion-sensing games can incorporate activities such as jumping, striking, balance, coordination, and whole-body movement into game tasks. For clinically stable children and adolescents with congenital heart disease, exergames may offer a feasible approach to promoting moderate-intensity physical activity in home settings when appropriate safety screening and guidance are provided.
This study will evaluate an exergame-based physical activity promotion intervention combined with behavioral support strategies. The intervention is designed to promote physical activity through individualized exercise guidance, goal setting, self-monitoring, feedback reinforcement, caregiver support, and safety monitoring. The intervention will be delivered over 12 weeks and will be adjusted according to each participant's clinical condition, exercise tolerance, participation experience, and adherence.
A multiple-baseline single-case experimental design will be used because children and adolescents with congenital heart disease may differ substantially in diagnosis, post-treatment status, exercise capacity, family support, and behavioral response. Each participant will serve as his or her own control. Participants will be randomly assigned to one of three baseline lengths: 7 days, 14 days, or 21 days. This staggered introduction of the intervention is intended to help distinguish intervention-related changes from natural changes over time.
The study will follow an A-B-A' structure. Phase A is the baseline phase, during which no formal exergame intervention will be provided and physical activity will be monitored continuously. Phase B is the 12-week intervention phase, during which participants will receive the Nintendo Switch-based exergame physical activity promotion intervention with behavioral support. Phase A' is a 2-week observation phase, during which intensive intervention support will stop and physical activity monitoring will continue to assess maintenance of intervention effects.
Participants will complete six assessment visits or time points: screening and baseline assessment, end of baseline, week 4 of intervention, week 8 of intervention, week 12 of intervention, and the end of the 2-week observation phase. Physical activity will be monitored repeatedly from baseline through the observation phase. The primary outcome is daily moderate-to-vigorous physical activity in minutes per day, measured using an ActiGraph wGT3X-BT triaxial accelerometer. Secondary outcomes include daily step counts, energy expenditure, self-reported physical activity, behavioral change-related psychological factors, cardiopulmonary fitness, 6-minute walk distance, heart rate-related indicators, body composition, and health-related quality of life. Feasibility, acceptability, adherence, and adverse events will also be recorded.
Data will be analyzed at both the individual and aggregated levels. Individual-level analyses will include visual analysis of level, trend, variability or stability, immediacy of effect, overlap, and consistency of patterns across participants. Time-series or segmented regression methods may be used to estimate level and trend changes across phases. Aggregated analyses will use linear mixed-effects models, with hierarchical Bayesian models considered as supplementary analyses, to estimate overall intervention effects and individual differences.
This study will provide preliminary evidence on the feasibility, acceptability, safety, and potential effectiveness of an exergame-based physical activity promotion intervention for children and adolescents with congenital heart disease. The findings may inform the development and optimization of digital physical activity promotion and rehabilitation strategies for this population.
991 studies on the registry are indexed under Heart Defects, Congenital; 251 are open to participants now.
This study's planned enrollment of 13 is below the median of 60 across 507 interventional studies indexed under Heart Defects, Congenital.
Browse Heart Defects, Congenital studies →The Children's Hospital of Zhejiang University School of Medicine is the lead sponsor of 69 studies on the registry; 52 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive an exergame-based physical activity promotion intervention using Nintendo Switch motion-sensing games. The study follows an A-B-A' structure. During the baseline phase, participants will be observed for 7, 14, or 21 days without the formal intervention. During the intervention phase, participants will receive a 12-week exergame-based physical activity program combined with behavioral support strategies, including individualized guidance, goal setting, self-monitoring, feedback, and caregiver support. During the 2-week observation phase, intensive intervention support will stop and physical activity monitoring will continue.
Behavioral: Nintendo Switch-Based Exergame Physical Activity Promotion Intervention
The intervention is a 12-week physical activity promotion program based on Nintendo Switch motion-sensing exergames for children and adolescents with congenital heart disease. Participants will be guided to complete game-based physical activity tasks involving whole-body movement, balance, coordination, and moderate-intensity activity. The program combines exergame play with behavioral support strategies, including individualized exercise guidance, goal setting, self-monitoring, feedback, caregiver support, adherence monitoring, and safety education. The intervention will be adjusted according to each participant's clinical condition, exercise tolerance, participation experience, and adherence. Physical activity and adverse events will be monitored throughout the study.
Daily Moderate-to-Vigorous Physical Activity (MVPA) Time
Daily moderate-to-vigorous physical activity (MVPA), expressed as minutes per day, will be objectively measured using an ActiGraph wGT3X-BT triaxial accelerometer worn on the dominant wrist during waking hours. Raw acceleration data will be collected at 30 Hz and processed into 5-second epochs. Non-wear time will be defined as at least 90 consecutive minutes of zero counts. A valid day will be defined as at least 10 hours of waking wear time. MVPA will be classified using wrist-based cut-points, with MVPA defined as at least 610 counts per 5 seconds.
Time frame: Baseline phase, 12-week intervention phase, and 2-week observation phase; total duration 15 to 17 weeks
Daily Step Count
Daily step count will be derived from ActiGraph wGT3X-BT accelerometer data and expressed as the total number of steps per valid day.
Time frame: Daily from baseline through the end of the 2-week observation phase, up to 17 weeks.
Daily Sedentary Time
Daily sedentary time will be derived from ActiGraph wGT3X-BT accelerometer data. Sedentary time will be calculated as the sum of all valid 5-second epochs classified as sedentary behavior using the wrist-based cut-point of less than 100 counts per 5 seconds, and expressed as minutes per valid day.
Time frame: Daily from baseline through the end of the 2-week observation phase, up to 17 weeks.
Self-Reported Physical Activity
Self-reported physical activity will be assessed using the Chinese version of the International Physical Activity Questionnaire-Short Form (IPAQ-SF). The questionnaire assesses physical activity performed during the previous 7 days. Total physical activity volume will be calculated according to the IPAQ scoring protocol and expressed as metabolic equivalent minutes per week. MET-min/week will be calculated by multiplying the MET value assigned to each activity intensity by the reported minutes per day and days per week, and then summing across walking, moderate-intensity activity, and vigorous-intensity activity. The standard MET values are 3.3 for walking, 4.0 for moderate-intensity activity, and 8.0 for vigorous-intensity activity. The minimum possible value is 0 MET-min/week, and there is no fixed maximum value because the score depends on reported frequency and duration of physical activity. Higher values indicate greater self-reported physical activity volume.
Time frame: Weekly from baseline through the end of the 2-week observation phase, up to 17 weeks.
Affective Attitude Toward Physical Activity
Affective attitude toward physical activity will be assessed using Multi-Process Action Control (M-PAC) framework-related affective attitude items. Participants will rate their anticipated emotional responses to physical activity using three 7-point rating items, such as whether physical activity is enjoyable or exciting. The total score will be calculated by summing the item scores. Scores range from 3 to 21, with higher scores indicating a more favorable affective attitude toward physical activity.
Time frame: Weekly from baseline through the end of the 2-week observation phase, up to 17 weeks.
Instrumental Attitude Toward Physical Activity
Instrumental attitude toward physical activity will be assessed using M-PAC framework-related instrumental attitude items. Participants will rate the perceived value or utility of physical activity using three 7-point rating items, such as whether physical activity is wise or beneficial. The total score will be calculated by summing the item scores. Scores range from 3 to 21, with higher scores indicating a more favorable instrumental attitude toward physical activity.
Time frame: Weekly from baseline through the end of the 2-week observation phase, up to 17 weeks
Perceived Capability for Physical Activity
Perceived capability for physical activity will be assessed using M-PAC framework-related perceived capability items. Participants will rate their perceived ability to engage in physical activity using three 5-point Likert items. The total score will be calculated by summing the item scores. Scores range from 3 to 15, with higher scores indicating greater perceived capability for physical activity.
Time frame: Weekly from baseline through the end of the 2-week observation phase, up to 17 weeks
Perceived Opportunity for Physical Activity
Perceived opportunity for physical activity will be assessed using M-PAC framework-related perceived opportunity items. Participants will rate their perceived environmental or contextual support for engaging in physical activity using three 5-point Likert items. The total score will be calculated by summing the item scores. Scores range from 3 to 15, with higher scores indicating greater perceived opportunity for physical activity.
Time frame: Weekly from baseline through the end of the 2-week observation phase, up to 17 weeks.
Action Planning for Physical Activity
Action planning for physical activity will be assessed using M-PAC framework-related three items that evaluate the extent to which participants have made specific plans for engaging in physical activity. The total score will be calculated by summing the item scores. Scores range from 3 to 15, with higher scores indicating stronger action planning for physical activity.
Time frame: Weekly from baseline through the end of the 2-week observation phase, up to 17 weeks.
Coping Planning for Physical Activity
Coping planning for physical activity will be assessed using using M-PAC framework-related three items that evaluate the extent to which participants have made plans to overcome anticipated barriers to physical activity. The total score will be calculated by summing the item scores. Scores range from 3 to 15, with higher scores indicating stronger coping planning for physical activity.
Time frame: Weekly from baseline through the end of the 2-week observation phase, up to 17 weeks.
Physical Activity Habit Strength
Physical activity habit strength will be assessed using the Self-Report Behavioral Automaticity Index. This measure includes four items assessing the extent to which physical activity has become automatic or habitual. The total score will be calculated by summing the item scores. Scores range from 4 to 28, with higher scores indicating stronger physical activity habit strength.
Time frame: Weekly from baseline through the end of the 2-week observation phase, up to 17 weeks.
Physical Activity Identity
Physical activity identity will be assessed using the role identity dimension of the Exercise Identity Scale. This measure includes four items assessing the extent to which participants identify themselves as physically active individuals. The total score will be calculated by summing the item scores. Scores range from 4 to 28, with higher scores indicating stronger physical activity identity.
Time frame: Weekly from baseline through the end of the 2-week observation phase, up to 17 weeks.
peak oxygen uptake (VO₂peak)
peak oxygen uptake (VO₂peak) will be obtained from cardiopulmonary exercise testing (CEPT) when the participant is clinically eligible and able to complete the test. It will be expressed relative to body mass as mL/kg/min and used as an indicator of aerobic exercise capacity.
Time frame: At baseline and immediately after the 12-week intervention
Six-Minute Walk Test Distance
Functional exercise tolerance will be assessed using the 6-minute walk test (6MWT). The test will be performed according to a standardized protocol on a flat, straight walking course. Participants will be instructed to walk as far as possible within 6 minutes, and the total distance walked will be recorded in meters. The 6MWT distance will be used as a measure of submaximal functional capacity and daily-life-relevant exercise tolerance.
Time frame: At baseline and immediately after the 12-week intervention.
Body Mass Index (BMI)
Body mass index (BMI) will be calculated as weight in kilograms divided by height in meters squared. Height and weight will be measured using standardized anthropometric procedures. Age- and sex-adjusted BMI percentiles or BMI z-scores may also be calculated according to appropriate growth reference standards.
Time frame: At baseline and immediately after the 12-week intervention
Health-Related Quality of Life (HRQOL)
Health-Related Quality of Life (HRQOL) will be assessed using the Pediatric Quality of Life Inventory, including the PedsQL 4.0 Generic Core Scales and the PedsQL 3.0 Cardiac Module. Items will be transformed to a 0 to 100 scale, with higher scores indicating better health-related quality of life.
Time frame: At baseline and immediately after the 12-week intervention.
Social Validity
Social validity will be assessed using semi-structured interviews with participants and their caregivers after completion of the post-intervention observation phase. Interviews will explore perceptions of the intervention goals, procedures, outcomes, acceptability, feasibility, participation burden, family support, implementation barriers, perceived changes in physical activity or confidence, willingness to continue using exergames or other physical activity strategies, and suggestions for improvement.
Time frame: At the end of the 2-week post-intervention observation phase.
Plan to share: Undecided — Individual participant data will not be publicly shared because the study involves minors with congenital heart disease, a small sample size, and intensive longitudinal physical activity data, which may increase the risk of participant re-identification even after de-identification. Aggregate results will be reported in publications. Reasonable requests for additional information may be considered by the principal investigator and the ethics committee in accordance with institutional policies and participant privacy protections.
No publications or documents are linked to this record.
Start is estimated for Jul 2026; primary completion for Jul 2027, 12 months later.
Of 205 non-industry interventional studies with no phase under Heart Defects, Congenital, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 12 months is below that.
Counting every sponsor, half of 223 studies reached it within 34 months; a quarter within 17 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Children's Hospital of Zhejiang University School of Medicine